Top

BMC Cancer

Published in:

Open Access 01-12-2019 | NSCLC | Research article

A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC

Authors: Xiaoling Shang, Jia Liu, Zhenxiang Li, Jiamao Lin, Haiyong Wang

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

This study aimed to evaluate the feasibility and prognostic accuracy of incorporating the number of positive lymph nodes (PLN) into the TNM staging system for non-small cell lung cancer (NSCLC) patients.

Methods

We screened a total of 9539 patients with resected stage IA-IIIB non-small cell cancer between 2010 and 2015 from SEER database. The chi-square test was used to compare patient baseline characteristics and the X-tile model was applied to determine cut-off values for the number of PLN (nN). The X-tile model was used to screen three different cut-off values including nN = 0, nN1–3 and nN4-. Univariate and multivariate Cox proportional hazards regression models were used to analyze the influence of different variables on overall survival (OS). Kaplan-Meier and log-rank test were used to compare survival differences.

Results

Based on the nN cutoffs, we conducted the univariate and multivariate Cox proportional hazards regression. The result showed that nN stage was a significant prognostic factor affecting patients' OS (all P < 0.001). We reclassified the seventh edition TNM stages of the enrolled patients with stage IA-IIIB NSCLC according to the 5-year OS rate. Hypothesized TNM substage based on the location and the number of PLN was further calculated. Then we drew survival curves for each substage, including for the current TNM stage and the hypothesized TNM stage. From the comparison of survival curves, we found that the survival curve of each substage of the hypothesized TNM classification was proportional and well distributed compared with the current TNM classification (P < 0.001).

Conclusion

Revised TNM staging integrating locational pN stage and numerical nN stage was a more accurate prognostic determinant in patients with NSCLC.

Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. https://doi.org/10.1007/978-3-319-24223-1_1.PubMedCrossRef

Jernal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52(1):23–47.CrossRef

Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist. 2011;16(5):672–81.PubMedPubMedCentralCrossRef

Ihde DC, Minna JD. Non-small cell lung cancer: part I. biology, diagnosis and staging. Curr Probl Cancer. 1991;15:61–104.PubMed

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer. J Thorac Oncol. 2016;11:39–51.PubMedCrossRef

Fukui T, Mori S, Yokoi K, et al. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol. 2006;1:120–5.PubMedCrossRef

Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg. 2008;85:211–5.PubMedCrossRef

Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, Miller A, Reid M. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg. 2012;93(5):1614–9. https://doi.org/10.1016/j.athoracsur.2012.01.065 discussion 1619-20 Epub 2012 Mar 20.PubMedPubMedCentralCrossRef

Wei S, Asamura H, Kawachi R, Sakurai H, Watanabe S-i. Which is the better prognostic factor for resected non-small cell lung Cancer: the number of metastatic lymph nodes or the currently used nodal stage classification? J Thorac Oncol. 2011;6(2):310–8. https://doi.org/10.1097/JTO.0b013e3181ff9b45 PubMedCrossRef

10.

Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009. p. 181–93. Google Scholar

11.

Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg. 2000;232(3):362–71.PubMedPubMedCentralCrossRef

12.

Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung Cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.PubMedCrossRef

13.

Nicholson AG, Chansky K, Crowley J, Beyruti R, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(3):300–11. https://doi.org/10.1016/j.jtho.2015.10.008.PubMedCrossRef

14.

Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions. The IASCL Lung Cancer Staging Project: The new database to inform the eight edition of the TNM classification of lung cancer. J Thorac Oncol. 2014;9:1618–24. https://doi.org/10.1097/JTO.0000000000000334.PubMedCrossRef

15.

Cerfolio RJ, Buddhiwardhan O, Bryant AS, et al. The accuracy of integrated PET/CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1017–23.PubMedCrossRef

16.

Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol. 2012;4:128–34. https://doi.org/10.4329/wjr.v4.i4.128.PubMedPubMedCentralCrossRef

17.

Saji H, Tsuboi M, Yoshida K, et al. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol. 2011;6(11):1865–71.PubMedCrossRef

18.

Saji H, Tsuboi M, Shimada Y, et al. A proposal for combination of total number and anatomical location of involved lymph nodes for nodal classification in non-small cell lung cancer. Chest. 2013;143:1618–25. https://doi.org/10.1378/chest.12-0750.PubMedCrossRef

19.

Ding X, Hui Z, Dai H, Fan C, Men Y, Ji W, Liang J, Lv J, Zhou Z, Feng Q, Xiao Z, Chen D, Zhang H, Yin W, Lu N, He J, Wang L. A proposal for combination of lymph node ratio and anatomic location of involved lymph nodes for nodal classification in non-small cell lung Cancer. J Thorac Oncol. 2016;11(9):1565–73. https://doi.org/10.1016/j.jtho.2016.05.004. Epub 2016 May 17.PubMedCrossRef

20.

Matsuguma H, Oki I, Nakahara R, Ohata N, Igarashi S, Mori K, Endo S, Yokoi K. Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes. Eur J Cardiothorac Surg. 2012;41(1):19–24.PubMed

21.

Bria E, Milella M, Sperduti I, Alessandrini G, Visca P, Corzani F, Giannarelli D, Cerasoli V, Cuppone F, Cecere FL, Marchetti A, Sacco R, Mucilli F, Malatesta S, Guetti L, Vitale L, Ceribelli A, Rinaldi M, Terzoli E, Cognetti F, Facciolo F. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer. 2009;66(3):365–71.PubMedCrossRef

22.

Dehing-Oberije C, De Ruysscher D, van der Weide H, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Simons J, Teule J, Rahmy A, Thimister P, Steck H, Lambin P. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(4):1039–44 Epub 2007 Sep 24.PubMedCrossRef

23.

Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer lung Cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung Cancer. J Thorac Oncol. 2015;10:1675–84.PubMedCrossRef

24.

Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001;19(1):157–63.PubMedCrossRef

25.

Weir L, Speers C, D’yachkova Y, Olivotto IA. Prognostic signifi cance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol. 2002;20(7):1793–9.PubMedCrossRef

26.

Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167(3):1295–8.PubMedCrossRef

27.

Darling GE, Allen MS, Decker PA, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Sur geons oncology group Z0030 trial. Chest. 2011;139(5):1124–9.PubMedCrossRef

28.

Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer. 2009;115(4):851–8.PubMedCrossRef

29.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975-2016) - Linked To County Attributes - Total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission.

30.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. J Natl Compr Cancer Netw. 2014;12(12):1738–61.CrossRef

31.

Van Schil PE, Balduyck B, De Waele M, Hendriks JM, Hertoghs M, Lauwers P. Surgical treatment of early-stage non-small-cell lung cancer. EJC Suppl. 2013;11(2):110–22.PubMedPubMedCentralCrossRef

32.

Bradley JD, Paulus R, Graham MV, Ettinger DS, Johnstone DW, Pilepich MV, Machtay M, Komaki R, Atkins J, Curran WJ, Groupet RTO. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the radiation therapy oncology group-- RTOG 9705. J Clin Oncol. 2005;23(15):3480–7.PubMedCrossRef

33.

Hui Z, Dai H, Liang J, Lv J, Zhou Z, Feng Q, Xiao Z, Chen D, Zhang H, Yin W, Wang L. Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy. Thorac Cancer. 2015;6(3):346–53.PubMedPubMedCentralCrossRef

34.

Gomez DR, Komaki R. Postoperative radiation therapy for non-small cell lung cancer and thymic malignancies. Cancers (Basel). 2012;4(1):307–22.CrossRef

35.

Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for subclassification and implications. J Clin Oncol. 2000;18:2981–9.PubMedCrossRef

36.

Reif M, Socinski MA, Rivera MP. Evidence-based medicine in the treatment of non-small cell lung cancer. Clin Chest Med. 2000;21:107–20.PubMedCrossRef

37.

Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172–8.PubMedCrossRef

Title: A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC
Authors: Xiaoling Shang
Jia Liu
Zhenxiang Li
Jiamao Lin
Haiyong Wang
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5797-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer

Effects of subitems in the colorectal cancer screening protocol on the Chinese colorectal cancer screening program: an analysis based on natural community screening results

Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy

Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer

The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer